Author:
Spitz A,Young J M,Larsen L,Mattia-Goldberg C,Donnelly J,Chwalisz K
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference18 articles.
1. American Cancer Society. Cancer Facts and Figures 2010. Available at
http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
. Accessed 12 August 2010.
2. Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, Hait HI et al. Patients’ choice of treatment in Stage D prostate cancer. Urology 1989; 33 (5 Suppl): 57–62.
3. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531–1538.
4. McLeod DG . Hormonal therapy: historical perspective to future directions. Urology 2003; 61 (2 Suppl 1): 3–7.
5. Berges R, Bello U . Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006; 22: 649–655.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献